The Dual Antiplatelet Therapy Study (DAPT Study) | NCT00977938

Name	Class
Abbott	INDUSTRY
Boston Scientific Corporation	INDUSTRY
Bristol-Myers Squibb	INDUSTRY
Sanofi-Synthelabo

Label	Type	Description	Intervention Names
12m DAPT Study Arm	Placebo Comparator	This population consists of subjects enrolled in the study who are free from death, MI, stroke, repeat coronary revascularization, major bleeding, and ST 12 months after stent implantation and who are compliant with 12 months of dual antiplatelet therapy following stent implantation and who are subsequently randomized to receive 18 months of placebo treatment in addition to aspirin.	Drug: Placebo & Aspirin
30m DAPT Study Arm	Active Comparator	This population consists of subjects enrolled in the study who are free from death, MI, stroke, repeat coronary revascularization, major bleeding, and ST 12 months after stent implantation and who are compliant with 12 months of dual antiplatelet therapy following stent implantation and who are subsequently randomized to receive an additional 18 months of thienopyridine treatment in addition to aspirin.	Drug: Clopidogrel & Aspirin, Prasugrel & Aspirin

Name	Type	Description	Arm Group Labels	Other Names
Placebo & Aspirin	Drug		12m DAPT Study Arm
Clopidogrel & Aspirin, Prasugrel & Aspirin

Measure	Description	Time Frame
MACCE (Death, Myocardial Infarction or Stroke) - Randomized DES ITT	The coprimary efficacy endpoints were the cumulative incidence of MACCE and the cumulative incidence of ARC definite or probable stent thrombosis within randomized DES ITT patients between 12 and 30 months post procedure.	18 months (12-30 months post-index procedure)
Definite or Probable Stent Thrombosis (ST) - Randomized DES ITT	The coprimary efficacy endpoints were the cumulative incidence of MACCE and the cumulative incidence of definite or probable ST within randomized DES ITT patients between 12 and 30 months post procedure. ST was assessed according to the Academic Research Consortium (ARC) definitions.	18 months (12-30 months post-index procedure)
GUSTO Severe or Moderate Bleeding - Randomized DES ITT	The primary safety endpoint was moderate or severe bleeding within randomized DES ITT patients between 12 and 30 months post procedure. Bleeding was assessed according to the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries (GUSTO) criteria.	18 months (12-30 months post-index procedure)

Measure	Description	Time Frame
MACCE (Death, Myocardial Infarction or Stroke) - Propensity Matched DES vs. BMS	Secondary powered endpoint	33 months (0-33 months post-index procedure)
Definite or Probable Stent Thrombosis (ST) - Propensity Matched DES vs. BMS

Name	Affiliation	Role
Laura Mauri, MD, MSc	Brigham and Women's Hospital	Principal Investigator
Dean Kereiakes, MD, FACC	Christ Hospital Heart and Vascular Center	Principal Investigator

Facility	Status	City	State	ZIP	Country	Contacts
Thomas Hospital		Fairhope	Alabama	36532	United States
Mercy Gilbert Medical Center

PubMed Identifier	Type	Citation	Retractions
37449567	Derived	Faridi KF, Strom JB, Kundi H, Butala NM, Curtis JP, Gao Q, Song Y, Zheng L, Tamez H, Shen C, Secemsky EA, Yeh RW. Association Between Claims-Defined Frailty and Outcomes Following 30 Versus 12 Months of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention: Findings From the EXTEND-DAPT Study. J Am Heart Assoc. 2023 Jul 18;12(14):e029588. doi: 10.1161/JAHA.123.029588. Epub 2023 Jul 14.
32683645

ID	Title	Description
FG000	DES 30-month DAPT	Of the 22,866 DES enrolled pts, a total of 9,961 pts underwent randomization at 12 months (4,941 to 12m DAPT and 5,020 to 30m DAPT).
FG001	DES 12-month DAPT

Type

Title

Description

Population Description

Reporting Status

Anticipated Posting Date

Parameter Type

Dispersion Type

Unit of Measure

Calculate Percentage

Time Frame

Units Analyzed

Denominator Units Selected

Arm/Group Information

Denominators

Classes

Analyses

Primary

MACCE (Death, Myocardial Infarction or Stroke) - Randomized DES ITT

The coprimary efficacy endpoints were the cumulative incidence of MACCE and the cumulative incidence of ARC definite or probable stent thrombosis within randomized DES ITT patients between 12 and 30 months post procedure.

All randomized DES ITT patients; Patients were analyzed according to the treatment to which they were randomized (regardless of post-randomization compliance with the randomized treatment); Patients not experiencing the endpoint were censored at 30 months or at last known follow-up, whichever was earlier.

Posted

Number

percentage of patients (KM estimate)

18 months (12-30 months post-index procedure)

ID	Title	Description
OG000	DES 30-month DAPT	Patients who were treated with DES at the index procedure and were randomized at 12 months post procedure to receive a total of 30 months of DAPT
OG001	DES 12-month DAPT	Patients who were treated with DES at the index procedure and were randomized at 12 months post procedure to receive a total of 12 months of DAPT

Units	Counts
Participants	OG0005020 OG0014941

Title

Denominators

Categories

Title	Measurements
	OG0004.34 OG0015.92

Group IDs	Group Description	Statistical Method	Statistical Comment	P-Value	P-Value Comment	Parameter Type	Parameter Value	Dispersion Type	Dispersion Value	Confidence Interval Sides	Confidence Interval %	CI Lower Limit	CI Upper Limit	CI Lower Limit Comment	CI Upper Limit Comment	Estimate Comment	Tested Non-Inferiority	Non-Inferiority Type	Non-Inferiority Comment	Other Analysis Description
OG000 OG001	The primary efficacy analysis was a superiority analysis. We controlled the two-sided family-wise error rate of 0.05 across the two coprimary end points using the Hochberg-Benjamini method. With this method, the null hypothesis of randomized treatment equivalence is rejected if significance is achieved for both end points at a two-sided alpha level of 0.05 or for one end point at a two-sided alpha level of 0.025.	Log Rank		<0.001	P-value was stratified according to geographic region (NA, EU, or AU and NZ), thienopyridine received at the time of randomization, and presence or absence of risk factors for ST; P-value was adjudsted using the Benjamini Hochberg approach.	Hazard Ratio (HR)	0.71			2-Sided	95	0.59	0.85			30-month DAPT vs. 12-month DAPT; HR was stratified according to geographic region (NA, EU, or AU and NZ), thienopyridine drug received at the time of randomization, and presence or absence of risk factors for stent thrombosis.

Primary

Definite or Probable Stent Thrombosis (ST) - Randomized DES ITT

The coprimary efficacy endpoints were the cumulative incidence of MACCE and the cumulative incidence of definite or probable ST within randomized DES ITT patients between 12 and 30 months post procedure. ST was assessed according to the Academic Research Consortium (ARC) definitions.

Posted

Number

percentage of patients (KM estimate)

18 months (12-30 months post-index procedure)

ID	Title	Description
OG000	DES 30-month DAPT	Patients who were treated with DES at the index procedure and were randomized at 12 months post procedure to receive a total of 30 months of DAPT
OG001	DES 12-month DAPT	Patients who were treated with DES at the index procedure and were randomized at 12 months post procedure to receive a total of 12 months of DAPT

Units	Counts

Primary

GUSTO Severe or Moderate Bleeding - Randomized DES ITT

The primary safety endpoint was moderate or severe bleeding within randomized DES ITT patients between 12 and 30 months post procedure. Bleeding was assessed according to the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries (GUSTO) criteria.

Only patients who could be evaluated were included in this analysis (i.e., patients whose last contact date was ≥510 days after randomization or who had any adjudicated bleeding event at or before 540 days).

Posted

Number

percentage of patients

18 months (12-30 months post-index procedure)

ID	Title	Description
OG000	DES 30-month DAPT	Patients who were treated with DES at the index procedure and were randomized at 12 months post procedure to receive a total of 30 months of DAPT
OG001	DES 12-month DAPT	Patients who were treated with DES at the index procedure and were randomized at 12 months post procedure to receive a total of 12 months of DAPT

Units	Counts
Participants

Secondary

MACCE (Death, Myocardial Infarction or Stroke) - Propensity Matched DES vs. BMS

Secondary powered endpoint

A subsample created by matching BMS- to DES-treated patients exactly on prevalence of STEMI and then matching on remaining baseline characteristics via propensity score, using a caliper width of 0.10. A BMS-treated patient was matched to a variable number of DES-treated patients without replacement, up to a maximum of 8.

Posted

Number

percentage of patients

33 months (0-33 months post-index procedure)

ID	Title	Description
OG000	Propensity-matched DES	Because patients were not randomized to DES or BMS, DES comparisons vs. BMS on stent thrombosis and MACCE were carried out on sample matched on baseline characteristics via propensity score matching. The analyses were restricted to patients enrolled into the 3 contributing studies that planned to follow all enrolled patients (whether or not a patient was randomized) for 33 months. Patients prematurely withdrawing before 29 months follow-up (earliest allowable follow-up time for the 30-month visit) or before experiencing the endpoint were excluded. A total of 13,257 DES-treated patients were eligible for propensity matching, of whom 8,308 patients were matched to BMS-treated patients (up to 8 DES patients could be matched to a BMS patient; i.e., the BMS:DES matching ratio ranged from 1:1 to 1:8).
OG001	Propensity-matched BMS	Because patients were not randomized to DES or BMS, DES comparisons vs. BMS on stent thrombosis and MACCE were carried out on sample matched on baseline characteristics via propensity score matching. The analyses were restricted to patients enrolled into the 3 contributing studies that planned to follow all enrolled patients (whether or not a patient was randomized) for 33 months. Patients prematurely withdrawing before 29 months follow-up (earliest allowable follow-up time for the 30-month visit) or before experiencing the endpoint were excluded. A total of 2,056 BMS-treated patients were eligible for propensity matching, of whom 1,718 were matched to at least one DES-treated patient (a BMS patient could be matched to up to 8 DES patients; i.e., the BMS:DES matching ratio ranged from 1:1 to 1:8).

Secondary

Definite or Probable Stent Thrombosis (ST) - Propensity Matched DES vs. BMS

Secondary powered endpoint

Posted

Number

percentage of patients

33 months (0-33 months post-index procedure)

ID	Title	Description
OG000	Propensity-matched DES	Because patients were not randomized to DES or BMS, DES comparisons vs. BMS on stent thrombosis and MACCE were carried out on sample matched on baseline characteristics via propensity score matching. The analyses were restricted to patients enrolled into the 3 contributing studies that planned to follow all enrolled patients (whether or not a patient was randomized) for 33 months. Patients prematurely withdrawing before 29 months follow-up (earliest allowable follow-up time for the 30-month visit) or before experiencing the endpoint were excluded. A total of 13,257 DES-treated patients were eligible for propensity matching, of whom 8,308 patients were matched to BMS-treated patients (up to 8 DES patients could be matched to a BMS patient; i.e., the BMS:DES matching ratio ranged from 1:1 to 1:8).
OG001	Propensity-matched BMS	Because patients were not randomized to DES or BMS, DES comparisons vs. BMS on stent thrombosis and MACCE were carried out on sample matched on baseline characteristics via propensity score matching. The analyses were restricted to patients enrolled into the 3 contributing studies that planned to follow all enrolled patients (whether or not a patient was randomized) for 33 months. Patients prematurely withdrawing before 29 months follow-up (earliest allowable follow-up time for the 30-month visit) or before experiencing the endpoint were excluded. A total of 2,056 BMS-treated patients were eligible for propensity matching, of whom 1,718 were matched to at least one DES-treated patient (a BMS patient could be matched to up to 8 DES patients; i.e., the BMS:DES matching ratio ranged from 1:1 to 1:8).

Secondary

MACCE (Death, Myocardial Infarction or Stroke) - Randomized DES ITT

All randomized DES ITT patients; Patients were analyzed according to the treatment to which they were randomized (regardless of post-randomization compliance with the randomized treatment); Patients not experiencing the endpoint were censored at 33 months or at last known follow-up, whichever was earlier.

Posted

Number

percentage of patients (KM estimate)

21 months (12-33 months post-index procedure)

ID	Title	Description
OG000	DES 30-month DAPT	Patients who were treated with DES at the index procedure and were randomized at 12 months post procedure to receive a total of 30 months of DAPT
OG001	DES 12-month DAPT	Patients who were treated with DES at the index procedure and were randomized at 12 months post procedure to receive a total of 12 months of DAPT

Units	Counts
Participants	OG000

Secondary

Definite or Probable Stent Thrombosis (ST) - Randomized DES ITT

ST was assessed according to the Academic Research Consortium (ARC) definitions.

All randomized DES ITT patients; Patients were analyzed according to the treatment to which they were randomized (regardless of post-randomization compliance with the randomized treatment); Patients not experiencing the endpoint were censored at 33 months or at last known follow-up, whichever was earlier.

Posted

Number

percentage of patients (KM estimate)

21 months (12-33 months post-index procedure)

ID	Title	Description
OG000	DES 30-month DAPT	Patients who were treated with DES at the index procedure and were randomized at 12 months post procedure to receive a total of 30 months of DAPT
OG001	DES 12-month DAPT	Patients who were treated with DES at the index procedure and were randomized at 12 months post procedure to receive a total of 12 months of DAPT

Units	Counts
Participants

Secondary

GUSTO Severe or Moderate Bleeding - Randomized DES ITT

Bleeding was assessed according to the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries (GUSTO) criteria.

Only patients who could be evaluated were included in this analysis (i.e., patients whose last contact date was ≥600 days after randomization or who had any adjudicated bleeding event at or before 630 days).

Posted

Number

percentage of patients

21 months (12-33 months post-index procedure)

ID	Title	Description
OG000	DES 30-month DAPT	Patients who were treated with DES at the index procedure and were randomized at 12 months post procedure to receive a total of 30 months of DAPT
OG001	DES 12-month DAPT	Patients who were treated with DES at the index procedure and were randomized at 12 months post procedure to receive a total of 12 months of DAPT

Units	Counts
Participants	OG000

Secondary

MACCE (Death, Myocardial Infarction or Stroke) - Randomized BMS ITT

All randomized BMS ITT patients; Patients were analyzed according to the treatment to which they were randomized (regardless of post-randomization compliance with the randomized treatment); Patients not experiencing the endpoint were censored at 30 months or at last known follow-up, whichever was earlier.

Posted

Number

percentage of patients (KM estimate)

18 months (12-30 months post-index procedure)

ID	Title	Description
OG000	BMS 30-month DAPT	Patients who were treated with BMS at the index procedure and were randomized at 12 months post procedure to receive a total of 30 months of DAPT
OG001	BMS 12-month DAPT	Patients who were treated with BMS at the index procedure and were randomized at 12 months post procedure to receive a total of 12 months of DAPT

Units	Counts
Participants	OG000

Secondary

Definite or Probable Stent Thrombosis (ST) - Randomized BMS ITT

ST was assessed according to the Academic Research Consortium (ARC) definitions.

Posted

Number

percentage of patients (KM estimate)

18 months (12-30 months post-index procedure)

ID	Title	Description
OG000	BMS 30-month DAPT	Patients who were treated with BMS at the index procedure and were randomized at 12 months post procedure to receive a total of 30 months of DAPT
OG001	BMS 12-month DAPT	Patients who were treated with BMS at the index procedure and were randomized at 12 months post procedure to receive a total of 12 months of DAPT

Units	Counts
Participants

Secondary

GUSTO Severe or Moderate Bleeding - Randomized BMS ITT

Bleeding was assessed according to the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries (GUSTO) criteria.

Posted

Number

percentage of patients

18 months (12-30 months post-index procedure)

ID	Title	Description
OG000	BMS 30-month DAPT	Patients who were treated with BMS at the index procedure and were randomized at 12 months post procedure to receive a total of 30 months of DAPT
OG001	BMS 12-month DAPT	Patients who were treated with BMS at the index procedure and were randomized at 12 months post procedure to receive a total of 12 months of DAPT

Units	Counts
Participants	OG000

Secondary

MACCE (Death, Myocardial Infarction or Stroke) - Randomized BMS ITT

All randomized BMS ITT patients; Patients were analyzed according to the treatment to which they were randomized (regardless of post-randomization compliance with the randomized treatment); Patients not experiencing the endpoint were censored at 33 months or at last known follow-up, whichever was earlier.

Posted

Number

percentage of patients (KM estimate)

21 months (12-33 months post-index procedure)

ID	Title	Description
OG000	BMS 30-month DAPT	Patients who were treated with BMS at the index procedure and were randomized at 12 months post procedure to receive a total of 30 months of DAPT
OG001	BMS 12-month DAPT	Patients who were treated with BMS at the index procedure and were randomized at 12 months post procedure to receive a total of 12 months of DAPT

Units	Counts
Participants	OG000

Secondary

Definite or Probable Stent Thrombosis (ST) - Randomized BMS ITT

ST was assessed according to the Academic Research Consortium (ARC) definitions.

All randomized BMS ITT patients; Patients were analyzed according to the treatment to which they were randomized (regardless of post-randomization compliance with the randomized treatment); Patients not experiencing the endpoint were censored at 33 months or at last known follow-up, whichever was earlier.

Posted

Number

percentage of patients (KM estimate)

21 months (12-33 months post-index procedure)

ID	Title	Description
OG000	BMS 30-month DAPT	Patients who were treated with BMS at the index procedure and were randomized at 12 months post procedure to receive a total of 30 months of DAPT
OG001	BMS 12-month DAPT	Patients who were treated with BMS at the index procedure and were randomized at 12 months post procedure to receive a total of 12 months of DAPT

Units	Counts
Participants

Secondary

GUSTO Severe or Moderate Bleeding - Randomized BMS ITT

Bleeding was assessed according to the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries (GUSTO) criteria.

Posted

Number

percentage of patients

21 months (12-33 months post-index procedure)

ID	Title	Description
OG000	BMS 30-month DAPT	Patients who were treated with BMS at the index procedure and were randomized at 12 months post procedure to receive a total of 30 months of DAPT
OG001	BMS 12-month DAPT	Patients who were treated with BMS at the index procedure and were randomized at 12 months post procedure to receive a total of 12 months of DAPT

Units	Counts
Participants	OG000

Serious Adverse Events

Term	Organ System	Statistical Information
ANAEMIA	Blood and lymphatic system disorders	EG00012 affected2,642 at risk EG0019 affected2,634 at risk EG0021 affected842 at risk EG0031 affected845 at risk
ANAEMIA OF CHRONIC DISEASE	Blood and lymphatic system disorders	EG0002 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
COAGULOPATHY	Blood and lymphatic system disorders	EG0000 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
IRON DEFICIENCY ANAEMIA	Blood and lymphatic system disorders	EG0001 affected2,642 at risk EG0013 affected2,634 at risk EG0021 affected842 at risk EG003
RETROPERITONEAL LYMPHADENOPATHY	Blood and lymphatic system disorders	EG0000 affected2,642 at risk EG0011 affected2,634 at risk EG0020 affected842 at risk EG003
SPLENIC INFARCTION	Blood and lymphatic system disorders	EG0000 affected2,642 at risk EG0010 affected2,634 at risk EG0021 affected842 at risk EG003
THROMBOCYTOPENIA	Blood and lymphatic system disorders	EG0001 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
ACUTE CORONARY SYNDROME	Cardiac disorders	EG0000 affected2,642 at risk EG0011 affected2,634 at risk EG0020 affected842 at risk EG003
ANGINA PECTORIS	Cardiac disorders	EG00055 affected2,642 at risk EG00155 affected2,634 at risk EG00213 affected842 at risk EG003
ANGINA UNSTABLE	Cardiac disorders	EG00027 affected2,642 at risk EG00140 affected2,634 at risk EG0024 affected842 at risk EG003
AORTIC VALVE INCOMPETENCE	Cardiac disorders	EG0000 affected2,642 at risk EG0011 affected2,634 at risk EG0020 affected842 at risk EG003
ARRHYTHMIA	Cardiac disorders	EG0003 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
ARTERIOSCLEROSIS CORONARY ARTERY	Cardiac disorders	EG0001 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
ARTERIOSPASM CORONARY	Cardiac disorders	EG0000 affected2,642 at risk EG0011 affected2,634 at risk EG0021 affected842 at risk EG003
ATRIAL FIBRILLATION	Cardiac disorders	EG00024 affected2,642 at risk EG00114 affected2,634 at risk EG0023 affected842 at risk EG003
ATRIAL FLUTTER	Cardiac disorders	EG0002 affected2,642 at risk EG0016 affected2,634 at risk EG0021 affected842 at risk EG003
ATRIAL TACHYCARDIA	Cardiac disorders	EG0001 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
ATRIOVENTRICULAR BLOCK	Cardiac disorders	EG0000 affected2,642 at risk EG0011 affected2,634 at risk EG0020 affected842 at risk EG003
ATRIOVENTRICULAR BLOCK COMPLETE	Cardiac disorders	EG0001 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
BRADYCARDIA	Cardiac disorders	EG0002 affected2,642 at risk EG0015 affected2,634 at risk EG0021 affected842 at risk EG003
BUNDLE BRANCH BLOCK LEFT	Cardiac disorders	EG0000 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
CARDIAC ARREST	Cardiac disorders	EG0008 affected2,642 at risk EG0019 affected2,634 at risk EG0022 affected842 at risk EG003
CARDIAC DISORDER	Cardiac disorders	EG0000 affected2,642 at risk EG0010 affected2,634 at risk EG0021 affected842 at risk EG003
CARDIAC FAILURE	Cardiac disorders	EG0005 affected2,642 at risk EG0017 affected2,634 at risk EG0022 affected842 at risk EG003
CARDIAC FAILURE ACUTE	Cardiac disorders	EG0000 affected2,642 at risk EG0011 affected2,634 at risk EG0022 affected842 at risk EG003
CARDIAC FAILURE CONGESTIVE	Cardiac disorders	EG00022 affected2,642 at risk EG00114 affected2,634 at risk EG0024 affected842 at risk EG003
CARDIO-RESPIRATORY ARREST	Cardiac disorders	EG0000 affected2,642 at risk EG0012 affected2,634 at risk EG0021 affected842 at risk EG003
CARDIOGENIC SHOCK	Cardiac disorders	EG0001 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
CARDIOMYOPATHY	Cardiac disorders	EG0001 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
CARDIOPULMONARY FAILURE	Cardiac disorders	EG0001 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
CONGESTIVE CARDIOMYOPATHY	Cardiac disorders	EG0001 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
CORONARY ARTERY DISEASE	Cardiac disorders	EG00022 affected2,642 at risk EG00116 affected2,634 at risk EG0029 affected842 at risk EG003
CORONARY ARTERY DISSECTION	Cardiac disorders	EG0000 affected2,642 at risk EG0011 affected2,634 at risk EG0020 affected842 at risk EG003
CORONARY ARTERY OCCLUSION	Cardiac disorders	EG0002 affected2,642 at risk EG0011 affected2,634 at risk EG0021 affected842 at risk EG003
CORONARY ARTERY STENOSIS	Cardiac disorders	EG0005 affected2,642 at risk EG0017 affected2,634 at risk EG0020 affected842 at risk EG003
EXTRASYSTOLES	Cardiac disorders	EG0001 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
ISCHAEMIC CARDIOMYOPATHY	Cardiac disorders	EG0002 affected2,642 at risk EG0010 affected2,634 at risk EG0021 affected842 at risk EG003
LEFT VENTRICULAR DYSFUNCTION	Cardiac disorders	EG0001 affected2,642 at risk EG0011 affected2,634 at risk EG0020 affected842 at risk EG003
LEFT VENTRICULAR FAILURE	Cardiac disorders	EG0000 affected2,642 at risk EG0011 affected2,634 at risk EG0020 affected842 at risk EG003
MITRAL VALVE INCOMPETENCE	Cardiac disorders	EG0001 affected2,642 at risk EG0011 affected2,634 at risk EG0020 affected842 at risk EG003
MYOCARDIAL ISCHAEMIA	Cardiac disorders	EG0002 affected2,642 at risk EG0011 affected2,634 at risk EG0020 affected842 at risk EG003
PALPITATIONS	Cardiac disorders	EG0001 affected2,642 at risk EG0014 affected2,634 at risk EG0020 affected842 at risk EG003
PERICARDIAL EFFUSION	Cardiac disorders	EG0001 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
PERICARDITIS	Cardiac disorders	EG0001 affected2,642 at risk EG0011 affected2,634 at risk EG0021 affected842 at risk EG003
SICK SINUS SYNDROME	Cardiac disorders	EG0002 affected2,642 at risk EG0010 affected2,634 at risk EG0022 affected842 at risk EG003
SUBENDOCARDIAL ISCHAEMIA	Cardiac disorders	EG0000 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
SUPRAVENTRICULAR EXTRASYSTOLES	Cardiac disorders	EG0000 affected2,642 at risk EG0011 affected2,634 at risk EG0020 affected842 at risk EG003
SUPRAVENTRICULAR TACHYCARDIA	Cardiac disorders	EG0004 affected2,642 at risk EG0012 affected2,634 at risk EG0020 affected842 at risk EG003
TACHYCARDIA	Cardiac disorders	EG0001 affected2,642 at risk EG0011 affected2,634 at risk EG0020 affected842 at risk EG003
VENTRICULAR FIBRILLATION	Cardiac disorders	EG0001 affected2,642 at risk EG0012 affected2,634 at risk EG0020 affected842 at risk EG003
VENTRICULAR TACHYCARDIA	Cardiac disorders	EG0000 affected2,642 at risk EG0014 affected2,634 at risk EG0020 affected842 at risk EG003
ARTERIOVENOUS MALFORMATION	Congenital, familial and genetic disorders	EG0001 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
ATRIAL SEPTAL DEFECT	Congenital, familial and genetic disorders	EG0001 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
HYDROCELE	Congenital, familial and genetic disorders	EG0001 affected2,642 at risk EG0011 affected2,634 at risk EG0020 affected842 at risk EG003
MYOTONIC DYSTROPHY	Congenital, familial and genetic disorders	EG0001 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
EXOSTOSIS OF EXTERNAL EAR CANAL	Ear and labyrinth disorders	EG0000 affected2,642 at risk EG0010 affected2,634 at risk EG0021 affected842 at risk EG003
MENIERE'S DISEASE	Ear and labyrinth disorders	EG0000 affected2,642 at risk EG0011 affected2,634 at risk EG0020 affected842 at risk EG003
VERTIGO	Ear and labyrinth disorders	EG0002 affected2,642 at risk EG0015 affected2,634 at risk EG0020 affected842 at risk EG003
HYPERPARATHYROIDISM	Endocrine disorders	EG0000 affected2,642 at risk EG0011 affected2,634 at risk EG0020 affected842 at risk EG003
HYPOTHYROIDISM	Endocrine disorders	EG0001 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
INAPPROPRIATE ANTIDIURETIC HORMONE SECRETION	Endocrine disorders	EG0000 affected2,642 at risk EG0011 affected2,634 at risk EG0020 affected842 at risk EG003
THYROID MASS	Endocrine disorders	EG0000 affected2,642 at risk EG0011 affected2,634 at risk EG0020 affected842 at risk EG003
CATARACT	Eye disorders	EG0002 affected2,642 at risk EG0010 affected2,634 at risk EG0021 affected842 at risk EG003
EYE PAIN	Eye disorders	EG0000 affected2,642 at risk EG0011 affected2,634 at risk EG0020 affected842 at risk EG003
GLAUCOMA	Eye disorders	EG0000 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
MACULAR DEGENERATION	Eye disorders	EG0000 affected2,642 at risk EG0011 affected2,634 at risk EG0020 affected842 at risk EG003
RETINAL DETACHMENT	Eye disorders	EG0000 affected2,642 at risk EG0011 affected2,634 at risk EG0021 affected842 at risk EG003
RETINAL HAEMORRHAGE	Eye disorders	EG0000 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
VISUAL ACUITY REDUCED	Eye disorders	EG0002 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
ABDOMINAL HERNIA	Gastrointestinal disorders	EG0000 affected2,642 at risk EG0011 affected2,634 at risk EG0020 affected842 at risk EG003
ABDOMINAL PAIN	Gastrointestinal disorders	EG0003 affected2,642 at risk EG0011 affected2,634 at risk EG0021 affected842 at risk EG003
ABDOMINAL PAIN LOWER	Gastrointestinal disorders	EG0001 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
ABDOMINAL PAIN UPPER	Gastrointestinal disorders	EG0001 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
APHTHOUS STOMATITIS	Gastrointestinal disorders	EG0001 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
ASCITES	Gastrointestinal disorders	EG0001 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
COLITIS	Gastrointestinal disorders	EG0001 affected2,642 at risk EG0012 affected2,634 at risk EG0020 affected842 at risk EG003
COLITIS ISCHAEMIC	Gastrointestinal disorders	EG0002 affected2,642 at risk EG0011 affected2,634 at risk EG0021 affected842 at risk EG003
COLITIS ULCERATIVE	Gastrointestinal disorders	EG0000 affected2,642 at risk EG0011 affected2,634 at risk EG0020 affected842 at risk EG003
CROHN'S DISEASE	Gastrointestinal disorders	EG0002 affected2,642 at risk EG0010 affected2,634 at risk EG0021 affected842 at risk EG003
DIARRHOEA	Gastrointestinal disorders	EG0002 affected2,642 at risk EG0011 affected2,634 at risk EG0022 affected842 at risk EG003
DIVERTICULAR PERFORATION	Gastrointestinal disorders	EG0001 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
DIVERTICULUM	Gastrointestinal disorders	EG0000 affected2,642 at risk EG0011 affected2,634 at risk EG0020 affected842 at risk EG003
DIVERTICULUM INTESTINAL HAEMORRHAGIC	Gastrointestinal disorders	EG0001 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
DUODENITIS	Gastrointestinal disorders	EG0001 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
EPIPLOIC APPENDAGITIS	Gastrointestinal disorders	EG0001 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
GASTRIC ULCER	Gastrointestinal disorders	EG0001 affected2,642 at risk EG0011 affected2,634 at risk EG0020 affected842 at risk EG003
GASTRITIS	Gastrointestinal disorders	EG0002 affected2,642 at risk EG0010 affected2,634 at risk EG0021 affected842 at risk EG003
GASTRITIS EROSIVE	Gastrointestinal disorders	EG0001 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
GASTROINTESTINAL HAEMORRHAGE	Gastrointestinal disorders	EG00010 affected2,642 at risk EG0012 affected2,634 at risk EG0020 affected842 at risk EG003
GASTROINTESTINAL PAIN	Gastrointestinal disorders	EG0000 affected2,642 at risk EG0011 affected2,634 at risk EG0020 affected842 at risk EG003
GASTROOESOPHAGEAL REFLUX DISEASE	Gastrointestinal disorders	EG0000 affected2,642 at risk EG0012 affected2,634 at risk EG0023 affected842 at risk EG003
HAEMATOCHEZIA	Gastrointestinal disorders	EG0000 affected2,642 at risk EG0011 affected2,634 at risk EG0020 affected842 at risk EG003
HAEMORRHOIDAL HAEMORRHAGE	Gastrointestinal disorders	EG0001 affected2,642 at risk EG0011 affected2,634 at risk EG0020 affected842 at risk EG003
HAEMORRHOIDS	Gastrointestinal disorders	EG0000 affected2,642 at risk EG0012 affected2,634 at risk EG0020 affected842 at risk EG003
HIATUS HERNIA	Gastrointestinal disorders	EG0000 affected2,642 at risk EG0011 affected2,634 at risk EG0020 affected842 at risk EG003
IMPAIRED GASTRIC EMPTYING	Gastrointestinal disorders	EG0000 affected2,642 at risk EG0011 affected2,634 at risk EG0020 affected842 at risk EG003
INGUINAL HERNIA	Gastrointestinal disorders	EG0003 affected2,642 at risk EG0013 affected2,634 at risk EG0022 affected842 at risk EG003
INGUINAL HERNIA, OBSTRUCTIVE	Gastrointestinal disorders	EG0000 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
INTESTINAL ISCHAEMIA	Gastrointestinal disorders	EG0000 affected2,642 at risk EG0011 affected2,634 at risk EG0020 affected842 at risk EG003
INTESTINAL OBSTRUCTION	Gastrointestinal disorders	EG0000 affected2,642 at risk EG0011 affected2,634 at risk EG0020 affected842 at risk EG003
LARGE INTESTINE PERFORATION	Gastrointestinal disorders	EG0001 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
LOWER GASTROINTESTINAL HAEMORRHAGE	Gastrointestinal disorders	EG0000 affected2,642 at risk EG0010 affected2,634 at risk EG0021 affected842 at risk EG003
MELAENA	Gastrointestinal disorders	EG0001 affected2,642 at risk EG0010 affected2,634 at risk EG0021 affected842 at risk EG003
NAUSEA	Gastrointestinal disorders	EG0001 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
OESOPHAGEAL PERFORATION	Gastrointestinal disorders	EG0000 affected2,642 at risk EG0011 affected2,634 at risk EG0020 affected842 at risk EG003
OESOPHAGEAL SPASM	Gastrointestinal disorders	EG0000 affected2,642 at risk EG0011 affected2,634 at risk EG0020 affected842 at risk EG003
OESOPHAGITIS	Gastrointestinal disorders	EG0001 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
PANCREATIC MASS	Gastrointestinal disorders	EG0000 affected2,642 at risk EG0011 affected2,634 at risk EG0020 affected842 at risk EG003
PANCREATIC PSEUDOCYST	Gastrointestinal disorders	EG0000 affected2,642 at risk EG0011 affected2,634 at risk EG0020 affected842 at risk EG003
PANCREATITIS	Gastrointestinal disorders	EG0002 affected2,642 at risk EG0012 affected2,634 at risk EG0021 affected842 at risk EG003
PANCREATITIS ACUTE	Gastrointestinal disorders	EG0003 affected2,642 at risk EG0013 affected2,634 at risk EG0020 affected842 at risk EG003
PHARYNGOESOPHAGEAL DIVERTICULUM	Gastrointestinal disorders	EG0001 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
POLYP COLORECTAL	Gastrointestinal disorders	EG0000 affected2,642 at risk EG0011 affected2,634 at risk EG0020 affected842 at risk EG003
RECTAL HAEMORRHAGE	Gastrointestinal disorders	EG0001 affected2,642 at risk EG0011 affected2,634 at risk EG0021 affected842 at risk EG003
RECTAL POLYP	Gastrointestinal disorders	EG0001 affected2,642 at risk EG0011 affected2,634 at risk EG0020 affected842 at risk EG003
SMALL INTESTINAL OBSTRUCTION	Gastrointestinal disorders	EG0001 affected2,642 at risk EG0015 affected2,634 at risk EG0021 affected842 at risk EG003
SPIGELIAN HERNIA	Gastrointestinal disorders	EG0001 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
UMBILICAL HERNIA	Gastrointestinal disorders	EG0002 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
UPPER GASTROINTESTINAL HAEMORRHAGE	Gastrointestinal disorders	EG0000 affected2,642 at risk EG0011 affected2,634 at risk EG0020 affected842 at risk EG003
VOLVULUS	Gastrointestinal disorders	EG0000 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
VOMITING	Gastrointestinal disorders	EG0000 affected2,642 at risk EG0010 affected2,634 at risk EG0021 affected842 at risk EG003
ADVERSE DRUG REACTION	General disorders	EG0000 affected2,642 at risk EG0011 affected2,634 at risk EG0020 affected842 at risk EG003
ASTHENIA	General disorders	EG0001 affected2,642 at risk EG0011 affected2,634 at risk EG0020 affected842 at risk EG003
CHEST DISCOMFORT	General disorders	EG0008 affected2,642 at risk EG0014 affected2,634 at risk EG0020 affected842 at risk EG003
CHEST PAIN	General disorders	EG00043 affected2,642 at risk EG00145 affected2,634 at risk EG00212 affected842 at risk EG003
DEATH	General disorders	EG0001 affected2,642 at risk EG0011 affected2,634 at risk EG0020 affected842 at risk EG003
HERNIA	General disorders	EG0001 affected2,642 at risk EG0010 affected2,634 at risk EG0022 affected842 at risk EG003
HERNIA OBSTRUCTIVE	General disorders	EG0000 affected2,642 at risk EG0012 affected2,634 at risk EG0021 affected842 at risk EG003
NON-CARDIAC CHEST PAIN	General disorders	EG00054 affected2,642 at risk EG00151 affected2,634 at risk EG00212 affected842 at risk EG003
OEDEMA PERIPHERAL	General disorders	EG0001 affected2,642 at risk EG0011 affected2,634 at risk EG0020 affected842 at risk EG003
PAIN	General disorders	EG0004 affected2,642 at risk EG0011 affected2,634 at risk EG0020 affected842 at risk EG003
PELVIC MASS	General disorders	EG0000 affected2,642 at risk EG0011 affected2,634 at risk EG0020 affected842 at risk EG003
PYREXIA	General disorders	EG0001 affected2,642 at risk EG0011 affected2,634 at risk EG0021 affected842 at risk EG003
SWELLING	General disorders	EG0003 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
SYSTEMIC INFLAMMATORY RESPONSE SYNDROME	General disorders	EG0001 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
ALCOHOLIC LIVER DISEASE	Hepatobiliary disorders	EG0001 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
BILE DUCT OBSTRUCTION	Hepatobiliary disorders	EG0001 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
BILE DUCT STENOSIS	Hepatobiliary disorders	EG0000 affected2,642 at risk EG0011 affected2,634 at risk EG0020 affected842 at risk EG003
BILE DUCT STONE	Hepatobiliary disorders	EG0000 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
BILIARY COLIC	Hepatobiliary disorders	EG0000 affected2,642 at risk EG0012 affected2,634 at risk EG0020 affected842 at risk EG003
CHOLANGITIS	Hepatobiliary disorders	EG0001 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
CHOLECYSTITIS	Hepatobiliary disorders	EG0005 affected2,642 at risk EG0012 affected2,634 at risk EG0020 affected842 at risk EG003
CHOLECYSTITIS ACUTE	Hepatobiliary disorders	EG0007 affected2,642 at risk EG0017 affected2,634 at risk EG0020 affected842 at risk EG003
CHOLELITHIASIS	Hepatobiliary disorders	EG0002 affected2,642 at risk EG0013 affected2,634 at risk EG0020 affected842 at risk EG003
CHOLESTASIS	Hepatobiliary disorders	EG0001 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
CHRONIC HEPATIC FAILURE	Hepatobiliary disorders	EG0001 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
HEPATIC CIRRHOSIS	Hepatobiliary disorders	EG0001 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
ALLERGY TO METALS	Immune system disorders	EG0000 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
ABDOMINAL WALL ABSCESS	Infections and infestations	EG0000 affected2,642 at risk EG0011 affected2,634 at risk EG0020 affected842 at risk EG003
ABSCESS	Infections and infestations	EG0000 affected2,642 at risk EG0012 affected2,634 at risk EG0020 affected842 at risk EG003
ABSCESS LIMB	Infections and infestations	EG0001 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
ANAL ABSCESS	Infections and infestations	EG0001 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
APPENDICITIS	Infections and infestations	EG0007 affected2,642 at risk EG0011 affected2,634 at risk EG0020 affected842 at risk EG003
APPENDICITIS PERFORATED	Infections and infestations	EG0001 affected2,642 at risk EG0011 affected2,634 at risk EG0020 affected842 at risk EG003
ARTERIOVENOUS GRAFT SITE INFECTION	Infections and infestations	EG0001 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
BACTERAEMIA	Infections and infestations	EG0002 affected2,642 at risk EG0011 affected2,634 at risk EG0021 affected842 at risk EG003
BRONCHIECTASIS	Infections and infestations	EG0001 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
BRONCHITIS	Infections and infestations	EG0005 affected2,642 at risk EG0015 affected2,634 at risk EG0022 affected842 at risk EG003
BRONCHITIS BACTERIAL	Infections and infestations	EG0001 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
BRONCHOPNEUMONIA	Infections and infestations	EG0002 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
CAMPYLOBACTER INTESTINAL INFECTION	Infections and infestations	EG0001 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
CELLULITIS	Infections and infestations	EG0008 affected2,642 at risk EG0019 affected2,634 at risk EG0021 affected842 at risk EG003
CELLULITIS STAPHYLOCOCCAL	Infections and infestations	EG0000 affected2,642 at risk EG0011 affected2,634 at risk EG0020 affected842 at risk EG003
CHOLECYSTITIS INFECTIVE	Infections and infestations	EG0000 affected2,642 at risk EG0011 affected2,634 at risk EG0020 affected842 at risk EG003
CLOSTRIDIAL INFECTION	Infections and infestations	EG0000 affected2,642 at risk EG0011 affected2,634 at risk EG0020 affected842 at risk EG003
CLOSTRIDIUM DIFFICILE COLITIS	Infections and infestations	EG0002 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
DIVERTICULITIS	Infections and infestations	EG0006 affected2,642 at risk EG0016 affected2,634 at risk EG0021 affected842 at risk EG003
ERYSIPELAS	Infections and infestations	EG0000 affected2,642 at risk EG0011 affected2,634 at risk EG0020 affected842 at risk EG003
ESCHERICHIA URINARY TRACT INFECTION	Infections and infestations	EG0001 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
GALLBLADDER ABSCESS	Infections and infestations	EG0000 affected2,642 at risk EG0010 affected2,634 at risk EG0021 affected842 at risk EG003
GANGRENE	Infections and infestations	EG0002 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
GASTRIC INFECTION	Infections and infestations	EG0001 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
GASTROENTERITIS	Infections and infestations	EG0003 affected2,642 at risk EG0012 affected2,634 at risk EG0020 affected842 at risk EG003
GASTROENTERITIS VIRAL	Infections and infestations	EG0002 affected2,642 at risk EG0011 affected2,634 at risk EG0020 affected842 at risk EG003
GIARDIASIS	Infections and infestations	EG0001 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
INFECTION	Infections and infestations	EG0002 affected2,642 at risk EG0011 affected2,634 at risk EG0020 affected842 at risk EG003
INFLUENZA	Infections and infestations	EG0002 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
INTERVERTEBRAL DISCITIS	Infections and infestations	EG0001 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
LOBAR PNEUMONIA	Infections and infestations	EG0002 affected2,642 at risk EG0012 affected2,634 at risk EG0020 affected842 at risk EG003
MASTOIDITIS	Infections and infestations	EG0001 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
MENINGITIS ASEPTIC	Infections and infestations	EG0001 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
NEUTROPENIC SEPSIS	Infections and infestations	EG0001 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
OSTEOMYELITIS	Infections and infestations	EG0002 affected2,642 at risk EG0012 affected2,634 at risk EG0020 affected842 at risk EG003
PANCREATIC ABSCESS	Infections and infestations	EG0000 affected2,642 at risk EG0011 affected2,634 at risk EG0020 affected842 at risk EG003
PHARYNGITIS	Infections and infestations	EG0000 affected2,642 at risk EG0011 affected2,634 at risk EG0020 affected842 at risk EG003
PILONIDAL CYST	Infections and infestations	EG0000 affected2,642 at risk EG0010 affected2,634 at risk EG0021 affected842 at risk EG003
PNEUMONIA	Infections and infestations	EG00021 affected2,642 at risk EG00117 affected2,634 at risk EG0024 affected842 at risk EG003
POSTOPERATIVE WOUND INFECTION	Infections and infestations	EG0002 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
PSEUDOMONAL SEPSIS	Infections and infestations	EG0001 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
PSEUDOMONAS INFECTION	Infections and infestations	EG0001 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
PYELONEPHRITIS	Infections and infestations	EG0003 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
PYELONEPHRITIS ACUTE	Infections and infestations	EG0001 affected2,642 at risk EG0011 affected2,634 at risk EG0020 affected842 at risk EG003
SEPSIS	Infections and infestations	EG0009 affected2,642 at risk EG0017 affected2,634 at risk EG0021 affected842 at risk EG003
SEPSIS SYNDROME	Infections and infestations	EG0000 affected2,642 at risk EG0011 affected2,634 at risk EG0020 affected842 at risk EG003
SINUSITIS	Infections and infestations	EG0000 affected2,642 at risk EG0011 affected2,634 at risk EG0020 affected842 at risk EG003
STAPHYLOCOCCAL BACTERAEMIA	Infections and infestations	EG0000 affected2,642 at risk EG0011 affected2,634 at risk EG0020 affected842 at risk EG003
STAPHYLOCOCCAL INFECTION	Infections and infestations	EG0001 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
STITCH ABSCESS	Infections and infestations	EG0001 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
UPPER RESPIRATORY TRACT INFECTION	Infections and infestations	EG0000 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
URINARY TRACT INFECTION	Infections and infestations	EG0005 affected2,642 at risk EG0017 affected2,634 at risk EG0022 affected842 at risk EG003
UROSEPSIS	Infections and infestations	EG0003 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
VIRAL INFECTION	Infections and infestations	EG0000 affected2,642 at risk EG0013 affected2,634 at risk EG0020 affected842 at risk EG003
WOUND INFECTION	Infections and infestations	EG0001 affected2,642 at risk EG0011 affected2,634 at risk EG0020 affected842 at risk EG003
BURNS THIRD DEGREE	Injury, poisoning and procedural complications	EG0001 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
CARTILAGE INJURY	Injury, poisoning and procedural complications	EG0001 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
CERVICAL VERTEBRAL FRACTURE	Injury, poisoning and procedural complications	EG0001 affected2,642 at risk EG0013 affected2,634 at risk EG0020 affected842 at risk EG003
CLAVICLE FRACTURE	Injury, poisoning and procedural complications	EG0000 affected2,642 at risk EG0011 affected2,634 at risk EG0020 affected842 at risk EG003
COLLAPSE OF LUNG	Injury, poisoning and procedural complications	EG0000 affected2,642 at risk EG0011 affected2,634 at risk EG0020 affected842 at risk EG003
COMPRESSION FRACTURE	Injury, poisoning and procedural complications	EG0000 affected2,642 at risk EG0010 affected2,634 at risk EG0021 affected842 at risk EG003
CONTUSION	Injury, poisoning and procedural complications	EG0002 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
CORONARY ARTERY RESTENOSIS	Injury, poisoning and procedural complications	EG0001 affected2,642 at risk EG0011 affected2,634 at risk EG0020 affected842 at risk EG003
CYSTITIS RADIATION	Injury, poisoning and procedural complications	EG0000 affected2,642 at risk EG0011 affected2,634 at risk EG0020 affected842 at risk EG003
DEVICE MALFUNCTION	Injury, poisoning and procedural complications	EG0001 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
FALL	Injury, poisoning and procedural complications	EG0004 affected2,642 at risk EG0012 affected2,634 at risk EG0020 affected842 at risk EG003
FEMORAL NECK FRACTURE	Injury, poisoning and procedural complications	EG0002 affected2,642 at risk EG0010 affected2,634 at risk EG0021 affected842 at risk EG003
FEMUR FRACTURE	Injury, poisoning and procedural complications	EG0001 affected2,642 at risk EG0012 affected2,634 at risk EG0020 affected842 at risk EG003
FOOT FRACTURE	Injury, poisoning and procedural complications	EG0001 affected2,642 at risk EG0011 affected2,634 at risk EG0021 affected842 at risk EG003
HEAD INJURY	Injury, poisoning and procedural complications	EG0000 affected2,642 at risk EG0012 affected2,634 at risk EG0020 affected842 at risk EG003
HEPATIC HAEMATOMA	Injury, poisoning and procedural complications	EG0001 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
HIP FRACTURE	Injury, poisoning and procedural complications	EG0001 affected2,642 at risk EG0013 affected2,634 at risk EG0022 affected842 at risk EG003
HUMERUS FRACTURE	Injury, poisoning and procedural complications	EG0000 affected2,642 at risk EG0011 affected2,634 at risk EG0020 affected842 at risk EG003
IN-STENT ARTERIAL RESTENOSIS	Injury, poisoning and procedural complications	EG0003 affected2,642 at risk EG0010 affected2,634 at risk EG0022 affected842 at risk EG003
IN-STENT CORONARY ARTERY RESTENOSIS	Injury, poisoning and procedural complications	EG00011 affected2,642 at risk EG0015 affected2,634 at risk EG0024 affected842 at risk EG003
INCISIONAL HERNIA	Injury, poisoning and procedural complications	EG0000 affected2,642 at risk EG0011 affected2,634 at risk EG0020 affected842 at risk EG003
INJURY	Injury, poisoning and procedural complications	EG0003 affected2,642 at risk EG0011 affected2,634 at risk EG0021 affected842 at risk EG003
JOINT DISLOCATION	Injury, poisoning and procedural complications	EG0001 affected2,642 at risk EG0012 affected2,634 at risk EG0020 affected842 at risk EG003
LACERATION	Injury, poisoning and procedural complications	EG0000 affected2,642 at risk EG0011 affected2,634 at risk EG0020 affected842 at risk EG003
LIMB INJURY	Injury, poisoning and procedural complications	EG0001 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
LOWER LIMB FRACTURE	Injury, poisoning and procedural complications	EG0000 affected2,642 at risk EG0011 affected2,634 at risk EG0020 affected842 at risk EG003
MENISCUS LESION	Injury, poisoning and procedural complications	EG0001 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
MULTIPLE FRACTURES	Injury, poisoning and procedural complications	EG0001 affected2,642 at risk EG0011 affected2,634 at risk EG0020 affected842 at risk EG003
MUSCLE RUPTURE	Injury, poisoning and procedural complications	EG0000 affected2,642 at risk EG0011 affected2,634 at risk EG0020 affected842 at risk EG003
OVERDOSE	Injury, poisoning and procedural complications	EG0000 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
POSTOPERATIVE ILEUS	Injury, poisoning and procedural complications	EG0000 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
PUBIC RAMI FRACTURE	Injury, poisoning and procedural complications	EG0001 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
RIB FRACTURE	Injury, poisoning and procedural complications	EG0001 affected2,642 at risk EG0011 affected2,634 at risk EG0020 affected842 at risk EG003
ROAD TRAFFIC ACCIDENT	Injury, poisoning and procedural complications	EG0002 affected2,642 at risk EG0010 affected2,634 at risk EG0021 affected842 at risk EG003
SKIN LACERATION	Injury, poisoning and procedural complications	EG0001 affected2,642 at risk EG0010 affected2,634 at risk EG0021 affected842 at risk EG003
SPINAL CORD INJURY	Injury, poisoning and procedural complications	EG0001 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
SPINAL FRACTURE	Injury, poisoning and procedural complications	EG0001 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
SUBDURAL HAEMATOMA	Injury, poisoning and procedural complications	EG0001 affected2,642 at risk EG0011 affected2,634 at risk EG0020 affected842 at risk EG003
SUBDURAL HAEMORRHAGE	Injury, poisoning and procedural complications	EG0000 affected2,642 at risk EG0011 affected2,634 at risk EG0020 affected842 at risk EG003
TENDON INJURY	Injury, poisoning and procedural complications	EG0001 affected2,642 at risk EG0011 affected2,634 at risk EG0020 affected842 at risk EG003
TENDON RUPTURE	Injury, poisoning and procedural complications	EG0001 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
THERMAL BURN	Injury, poisoning and procedural complications	EG0000 affected2,642 at risk EG0011 affected2,634 at risk EG0021 affected842 at risk EG003
THORACIC VERTEBRAL FRACTURE	Injury, poisoning and procedural complications	EG0001 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
THROMBOSIS IN DEVICE	Injury, poisoning and procedural complications	EG0000 affected2,642 at risk EG0011 affected2,634 at risk EG0020 affected842 at risk EG003
UPPER LIMB FRACTURE	Injury, poisoning and procedural complications	EG0001 affected2,642 at risk EG0011 affected2,634 at risk EG0020 affected842 at risk EG003
URETHRAL INJURY	Injury, poisoning and procedural complications	EG0001 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
URINARY BLADDER RUPTURE	Injury, poisoning and procedural complications	EG0000 affected2,642 at risk EG0011 affected2,634 at risk EG0020 affected842 at risk EG003
VASCULAR BYPASS DYSFUNCTION	Injury, poisoning and procedural complications	EG0000 affected2,642 at risk EG0011 affected2,634 at risk EG0020 affected842 at risk EG003
VASCULAR GRAFT OCCLUSION	Injury, poisoning and procedural complications	EG0000 affected2,642 at risk EG0010 affected2,634 at risk EG0021 affected842 at risk EG003
VASCULAR PSEUDOANEURYSM	Injury, poisoning and procedural complications	EG0002 affected2,642 at risk EG0011 affected2,634 at risk EG0020 affected842 at risk EG003
WOUND DEHISCENCE	Injury, poisoning and procedural complications	EG0002 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
ANTIMICROBIAL SUSCEPTIBILITY TEST RESISTANT	Investigations	EG0000 affected2,642 at risk EG0011 affected2,634 at risk EG0020 affected842 at risk EG003
BLOOD CREATININE	Investigations	EG0001 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
BLOOD GLUCOSE FLUCTUATION	Investigations	EG0001 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
BLOOD POTASSIUM INCREASED	Investigations	EG0000 affected2,642 at risk EG0011 affected2,634 at risk EG0020 affected842 at risk EG003
BRONCHOSCOPY	Investigations	EG0001 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
EJECTION FRACTION DECREASED	Investigations	EG0001 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
PROSTATIC SPECIFIC ANTIGEN INCREASED	Investigations	EG0001 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
TROPONIN I INCREASED	Investigations	EG0000 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
DEHYDRATION	Metabolism and nutrition disorders	EG0001 affected2,642 at risk EG0012 affected2,634 at risk EG0021 affected842 at risk EG003
DIABETES MELLITUS	Metabolism and nutrition disorders	EG0002 affected2,642 at risk EG0010 affected2,634 at risk EG0022 affected842 at risk EG003
DIABETIC FOOT	Metabolism and nutrition disorders	EG0001 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
FAILURE TO THRIVE	Metabolism and nutrition disorders	EG0001 affected2,642 at risk EG0011 affected2,634 at risk EG0021 affected842 at risk EG003
GOUT	Metabolism and nutrition disorders	EG0000 affected2,642 at risk EG0010 affected2,634 at risk EG0021 affected842 at risk EG003
HYPERCALCAEMIA	Metabolism and nutrition disorders	EG0000 affected2,642 at risk EG0011 affected2,634 at risk EG0020 affected842 at risk EG003
HYPERGLYCAEMIA	Metabolism and nutrition disorders	EG0002 affected2,642 at risk EG0013 affected2,634 at risk EG0020 affected842 at risk EG003
HYPERKALAEMIA	Metabolism and nutrition disorders	EG0003 affected2,642 at risk EG0013 affected2,634 at risk EG0020 affected842 at risk EG003
HYPOGLYCAEMIA	Metabolism and nutrition disorders	EG0001 affected2,642 at risk EG0013 affected2,634 at risk EG0020 affected842 at risk EG003
HYPOKALAEMIA	Metabolism and nutrition disorders	EG0000 affected2,642 at risk EG0012 affected2,634 at risk EG0020 affected842 at risk EG003
HYPONATRAEMIA	Metabolism and nutrition disorders	EG0001 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
METABOLIC ACIDOSIS	Metabolism and nutrition disorders	EG0000 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
OBESITY	Metabolism and nutrition disorders	EG0001 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
TYPE 2 DIABETES MELLITUS	Metabolism and nutrition disorders	EG0001 affected2,642 at risk EG0011 affected2,634 at risk EG0020 affected842 at risk EG003
ARTHRALGIA	Musculoskeletal and connective tissue disorders	EG0003 affected2,642 at risk EG0014 affected2,634 at risk EG0020 affected842 at risk EG003
ARTHRITIS	Musculoskeletal and connective tissue disorders	EG0008 affected2,642 at risk EG0015 affected2,634 at risk EG0021 affected842 at risk EG003
ARTHROPATHY	Musculoskeletal and connective tissue disorders	EG0001 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
BACK PAIN	Musculoskeletal and connective tissue disorders	EG0003 affected2,642 at risk EG0015 affected2,634 at risk EG0021 affected842 at risk EG003
CERVICAL SPINAL STENOSIS	Musculoskeletal and connective tissue disorders	EG0001 affected2,642 at risk EG0014 affected2,634 at risk EG0020 affected842 at risk EG003
CHONDROCALCINOSIS PYROPHOSPHATE	Musculoskeletal and connective tissue disorders	EG0000 affected2,642 at risk EG0011 affected2,634 at risk EG0020 affected842 at risk EG003
COMPARTMENT SYNDROME	Musculoskeletal and connective tissue disorders	EG0000 affected2,642 at risk EG0010 affected2,634 at risk EG0021 affected842 at risk EG003
COSTOCHONDRITIS	Musculoskeletal and connective tissue disorders	EG0001 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
FLANK PAIN	Musculoskeletal and connective tissue disorders	EG0000 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
FOOT DEFORMITY	Musculoskeletal and connective tissue disorders	EG0001 affected2,642 at risk EG0010 affected2,634 at risk EG0021 affected842 at risk EG003
GOUTY ARTHRITIS	Musculoskeletal and connective tissue disorders	EG0001 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
HAEMARTHROSIS	Musculoskeletal and connective tissue disorders	EG0001 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
INTERVERTEBRAL DISC DEGENERATION	Musculoskeletal and connective tissue disorders	EG0000 affected2,642 at risk EG0011 affected2,634 at risk EG0020 affected842 at risk EG003
INTERVERTEBRAL DISC DISORDER	Musculoskeletal and connective tissue disorders	EG0002 affected2,642 at risk EG0011 affected2,634 at risk EG0021 affected842 at risk EG003
INTERVERTEBRAL DISC PROTRUSION	Musculoskeletal and connective tissue disorders	EG0001 affected2,642 at risk EG0015 affected2,634 at risk EG0021 affected842 at risk EG003
LUMBAR SPINAL STENOSIS	Musculoskeletal and connective tissue disorders	EG0007 affected2,642 at risk EG0017 affected2,634 at risk EG0020 affected842 at risk EG003
MUSCLE SPASMS	Musculoskeletal and connective tissue disorders	EG0000 affected2,642 at risk EG0011 affected2,634 at risk EG0020 affected842 at risk EG003
MUSCULAR WEAKNESS	Musculoskeletal and connective tissue disorders	EG0000 affected2,642 at risk EG0010 affected2,634 at risk EG0021 affected842 at risk EG003
MUSCULOSKELETAL CHEST PAIN	Musculoskeletal and connective tissue disorders	EG0003 affected2,642 at risk EG0013 affected2,634 at risk EG0021 affected842 at risk EG003
MUSCULOSKELETAL PAIN	Musculoskeletal and connective tissue disorders	EG0003 affected2,642 at risk EG0011 affected2,634 at risk EG0020 affected842 at risk EG003
NECK PAIN	Musculoskeletal and connective tissue disorders	EG0003 affected2,642 at risk EG0011 affected2,634 at risk EG0021 affected842 at risk EG003
NEUROPATHIC ARTHROPATHY	Musculoskeletal and connective tissue disorders	EG0001 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
OSTEOARTHRITIS	Musculoskeletal and connective tissue disorders	EG00029 affected2,642 at risk EG00125 affected2,634 at risk EG0027 affected842 at risk EG003
OSTEOLYSIS	Musculoskeletal and connective tissue disorders	EG0000 affected2,642 at risk EG0011 affected2,634 at risk EG0020 affected842 at risk EG003
OSTEOPOROSIS	Musculoskeletal and connective tissue disorders	EG0000 affected2,642 at risk EG0010 affected2,634 at risk EG0021 affected842 at risk EG003
PAIN IN EXTREMITY	Musculoskeletal and connective tissue disorders	EG0002 affected2,642 at risk EG0012 affected2,634 at risk EG0020 affected842 at risk EG003
PAIN IN JAW	Musculoskeletal and connective tissue disorders	EG0001 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
RHABDOMYOLYSIS	Musculoskeletal and connective tissue disorders	EG0002 affected2,642 at risk EG0011 affected2,634 at risk EG0020 affected842 at risk EG003
RHEUMATOID ARTHRITIS	Musculoskeletal and connective tissue disorders	EG0000 affected2,642 at risk EG0011 affected2,634 at risk EG0020 affected842 at risk EG003
ROTATOR CUFF SYNDROME	Musculoskeletal and connective tissue disorders	EG0002 affected2,642 at risk EG0011 affected2,634 at risk EG0020 affected842 at risk EG003
SPINAL COLUMN STENOSIS	Musculoskeletal and connective tissue disorders	EG0001 affected2,642 at risk EG0011 affected2,634 at risk EG0020 affected842 at risk EG003
SPINAL OSTEOARTHRITIS	Musculoskeletal and connective tissue disorders	EG0002 affected2,642 at risk EG0013 affected2,634 at risk EG0021 affected842 at risk EG003
SPONDYLOARTHROPATHY	Musculoskeletal and connective tissue disorders	EG0000 affected2,642 at risk EG0011 affected2,634 at risk EG0020 affected842 at risk EG003
SPONDYLOLISTHESIS	Musculoskeletal and connective tissue disorders	EG0000 affected2,642 at risk EG0011 affected2,634 at risk EG0020 affected842 at risk EG003
TENDON DISORDER	Musculoskeletal and connective tissue disorders	EG0000 affected2,642 at risk EG0011 affected2,634 at risk EG0020 affected842 at risk EG003
ACUTE MYELOID LEUKAEMIA	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	EG0001 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
ADENOCARCINOMA	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	EG0003 affected2,642 at risk EG0011 affected2,634 at risk EG0020 affected842 at risk EG003
ADENOCARCINOMA PANCREAS	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	EG0001 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
ANGIOSARCOMA	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	EG0000 affected2,642 at risk EG0010 affected2,634 at risk EG0021 affected842 at risk EG003
B-CELL LYMPHOMA	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	EG0000 affected2,642 at risk EG0011 affected2,634 at risk EG0020 affected842 at risk EG003
BASAL CELL CARCINOMA	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	EG0003 affected2,642 at risk EG0014 affected2,634 at risk EG0021 affected842 at risk EG003
BENIGN DUODENAL NEOPLASM	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	EG0001 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
BLADDER CANCER	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	EG0002 affected2,642 at risk EG0012 affected2,634 at risk EG0022 affected842 at risk EG003
BLADDER CANCER RECURRENT	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	EG0001 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
BLADDER TRANSITIONAL CELL CARCINOMA	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	EG0001 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
BRAIN NEOPLASM	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	EG0002 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
BREAST CANCER	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	EG0004 affected2,642 at risk EG0014 affected2,634 at risk EG0020 affected842 at risk EG003
BREAST CANCER STAGE III	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	EG0000 affected2,642 at risk EG0011 affected2,634 at risk EG0020 affected842 at risk EG003
CARCINOID TUMOUR OF THE SMALL BOWEL	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	EG0000 affected2,642 at risk EG0010 affected2,634 at risk EG0021 affected842 at risk EG003
CARDIAC MYXOMA	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	EG0000 affected2,642 at risk EG0011 affected2,634 at risk EG0020 affected842 at risk EG003
CHRONIC LYMPHOCYTIC LEUKAEMIA	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	EG0001 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
CHRONIC MYELOMONOCYTIC LEUKAEMIA	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	EG0001 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
COLON CANCER	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	EG0004 affected2,642 at risk EG0013 affected2,634 at risk EG0023 affected842 at risk EG003
EXTRANODAL MARGINAL ZONE B-CELL LYMPHOMA (MALT TYPE)	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	EG0001 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
GASTRIC CANCER	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	EG0001 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
HEPATIC NEOPLASM MALIGNANT	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	EG0002 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
INTRAVASCULAR PAPILLARY ENDOTHELIAL HYPERPLASIA	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	EG0000 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
LANGERHANS' CELL GRANULOMATOSIS	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	EG0000 affected2,642 at risk EG0011 affected2,634 at risk EG0020 affected842 at risk EG003
LENTIGO MALIGNA STAGE UNSPECIFIED	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	EG0000 affected2,642 at risk EG0011 affected2,634 at risk EG0020 affected842 at risk EG003
LIP AND/OR ORAL CAVITY CANCER	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	EG0001 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
LIP NEOPLASM MALIGNANT STAGE UNSPECIFIED	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	EG0000 affected2,642 at risk EG0011 affected2,634 at risk EG0020 affected842 at risk EG003
LUNG CANCER METASTATIC	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	EG0001 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
LUNG CARCINOMA CELL TYPE UNSPECIFIED RECURRENT	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	EG0000 affected2,642 at risk EG0010 affected2,634 at risk EG0021 affected842 at risk EG003
LUNG NEOPLASM	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	EG0000 affected2,642 at risk EG0011 affected2,634 at risk EG0020 affected842 at risk EG003
LUNG NEOPLASM MALIGNANT	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	EG0005 affected2,642 at risk EG0012 affected2,634 at risk EG0021 affected842 at risk EG003
LYMPHOMA	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	EG0001 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
MALIGNANT MELANOMA	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	EG0000 affected2,642 at risk EG0012 affected2,634 at risk EG0020 affected842 at risk EG003
MALIGNANT MELANOMA STAGE II	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	EG0000 affected2,642 at risk EG0011 affected2,634 at risk EG0020 affected842 at risk EG003
METASTASES TO BONE	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	EG0001 affected2,642 at risk EG0011 affected2,634 at risk EG0020 affected842 at risk EG003
METASTASES TO CENTRAL NERVOUS SYSTEM	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	EG0001 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
METASTATIC NEOPLASM	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	EG0001 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
MULTIPLE MYELOMA	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	EG0000 affected2,642 at risk EG0011 affected2,634 at risk EG0020 affected842 at risk EG003
NEOPLASM MALIGNANT	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	EG0000 affected2,642 at risk EG0010 affected2,634 at risk EG0021 affected842 at risk EG003
NEOPLASM PROSTATE	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	EG0000 affected2,642 at risk EG0010 affected2,634 at risk EG0021 affected842 at risk EG003
NON-HODGKIN'S LYMPHOMA	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	EG0000 affected2,642 at risk EG0011 affected2,634 at risk EG0020 affected842 at risk EG003
NON-SMALL CELL LUNG CANCER	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	EG0002 affected2,642 at risk EG0011 affected2,634 at risk EG0020 affected842 at risk EG003
NON-SMALL CELL LUNG CANCER STAGE IV	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	EG0000 affected2,642 at risk EG0011 affected2,634 at risk EG0020 affected842 at risk EG003
OESOPHAGEAL ADENOCARCINOMA	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	EG0000 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
OESOPHAGEAL CARCINOMA	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	EG0000 affected2,642 at risk EG0012 affected2,634 at risk EG0020 affected842 at risk EG003
OVARIAN CANCER METASTATIC	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	EG0001 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
PANCREATIC CARCINOMA	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	EG0001 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
PITUITARY TUMOUR BENIGN	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	EG0001 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
PROSTATE CANCER	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	EG00013 affected2,642 at risk EG00110 affected2,634 at risk EG0020 affected842 at risk EG003
PROSTATE CANCER METASTATIC	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	EG0001 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
RECTAL CANCER	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	EG0001 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
RECTOSIGMOID CANCER	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	EG0000 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
RENAL CANCER	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	EG0000 affected2,642 at risk EG0011 affected2,634 at risk EG0020 affected842 at risk EG003
RENAL CELL CARCINOMA	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	EG0000 affected2,642 at risk EG0011 affected2,634 at risk EG0021 affected842 at risk EG003
SIGNET-RING CELL CARCINOMA	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	EG0000 affected2,642 at risk EG0011 affected2,634 at risk EG0020 affected842 at risk EG003
SKIN CANCER	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	EG0002 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
SMALL CELL LUNG CANCER METASTATIC	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	EG0001 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
SQUAMOUS CELL CARCINOMA	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	EG0002 affected2,642 at risk EG0012 affected2,634 at risk EG0021 affected842 at risk EG003
THYROID CANCER	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	EG0001 affected2,642 at risk EG0012 affected2,634 at risk EG0020 affected842 at risk EG003
TONGUE NEOPLASM MALIGNANT STAGE UNSPECIFIED	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	EG0000 affected2,642 at risk EG0011 affected2,634 at risk EG0020 affected842 at risk EG003
TRANSITIONAL CELL CARCINOMA	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	EG0002 affected2,642 at risk EG0011 affected2,634 at risk EG0020 affected842 at risk EG003
ANOXIC ENCEPHALOPATHY	Nervous system disorders	EG0000 affected2,642 at risk EG0011 affected2,634 at risk EG0020 affected842 at risk EG003
APHASIA	Nervous system disorders	EG0000 affected2,642 at risk EG0011 affected2,634 at risk EG0020 affected842 at risk EG003
ATAXIA	Nervous system disorders	EG0001 affected2,642 at risk EG0011 affected2,634 at risk EG0020 affected842 at risk EG003
BENIGN INTRACRANIAL HYPERTENSION	Nervous system disorders	EG0000 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
CAROTID ARTERY STENOSIS	Nervous system disorders	EG0008 affected2,642 at risk EG0016 affected2,634 at risk EG0021 affected842 at risk EG003
CEREBRAL HAEMATOMA	Nervous system disorders	EG0001 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
CEREBROVASCULAR ACCIDENT	Nervous system disorders	EG0001 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
CERVICOBRACHIAL SYNDROME	Nervous system disorders	EG0000 affected2,642 at risk EG0011 affected2,634 at risk EG0020 affected842 at risk EG003
CONVULSION	Nervous system disorders	EG0000 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
DEMENTIA	Nervous system disorders	EG0000 affected2,642 at risk EG0013 affected2,634 at risk EG0020 affected842 at risk EG003
DEMENTIA ALZHEIMER'S TYPE	Nervous system disorders	EG0001 affected2,642 at risk EG0010 affected2,634 at risk EG0021 affected842 at risk EG003
DEMYELINATION	Nervous system disorders	EG0000 affected2,642 at risk EG0011 affected2,634 at risk EG0020 affected842 at risk EG003
DIABETIC NEUROPATHY	Nervous system disorders	EG0001 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
DIZZINESS	Nervous system disorders	EG0005 affected2,642 at risk EG0014 affected2,634 at risk EG0020 affected842 at risk EG003
ENCEPHALOPATHY	Nervous system disorders	EG0001 affected2,642 at risk EG0011 affected2,634 at risk EG0020 affected842 at risk EG003
FACIAL PALSY	Nervous system disorders	EG0000 affected2,642 at risk EG0011 affected2,634 at risk EG0020 affected842 at risk EG003
GRAND MAL CONVULSION	Nervous system disorders	EG0002 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
HEADACHE	Nervous system disorders	EG0001 affected2,642 at risk EG0012 affected2,634 at risk EG0020 affected842 at risk EG003
HYPOAESTHESIA	Nervous system disorders	EG0001 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
INTRACRANIAL ANEURYSM	Nervous system disorders	EG0001 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
INTRACRANIAL HYPOTENSION	Nervous system disorders	EG0001 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
LOSS OF CONSCIOUSNESS	Nervous system disorders	EG0000 affected2,642 at risk EG0011 affected2,634 at risk EG0020 affected842 at risk EG003
METABOLIC ENCEPHALOPATHY	Nervous system disorders	EG0000 affected2,642 at risk EG0011 affected2,634 at risk EG0020 affected842 at risk EG003
MIGRAINE	Nervous system disorders	EG0001 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
MYOCLONUS	Nervous system disorders	EG0001 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
NEUROPATHY PERIPHERAL	Nervous system disorders	EG0001 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
PARKINSON'S DISEASE	Nervous system disorders	EG0000 affected2,642 at risk EG0010 affected2,634 at risk EG0021 affected842 at risk EG003
PERONEAL NERVE PALSY	Nervous system disorders	EG0001 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
POST HERPETIC NEURALGIA	Nervous system disorders	EG0001 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
POST-TRAUMATIC EPILEPSY	Nervous system disorders	EG0000 affected2,642 at risk EG0011 affected2,634 at risk EG0020 affected842 at risk EG003
PRESYNCOPE	Nervous system disorders	EG0002 affected2,642 at risk EG0012 affected2,634 at risk EG0020 affected842 at risk EG003
RADICULOPATHY	Nervous system disorders	EG0000 affected2,642 at risk EG0011 affected2,634 at risk EG0020 affected842 at risk EG003
REVERSIBLE POSTERIOR LEUKOENCEPHALOPATHY SYNDROME	Nervous system disorders	EG0000 affected2,642 at risk EG0010 affected2,634 at risk EG0021 affected842 at risk EG003
SCIATICA	Nervous system disorders	EG0000 affected2,642 at risk EG0012 affected2,634 at risk EG0020 affected842 at risk EG003
SENSORY DISTURBANCE	Nervous system disorders	EG0000 affected2,642 at risk EG0011 affected2,634 at risk EG0020 affected842 at risk EG003
SPINAL CLAUDICATION	Nervous system disorders	EG0001 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
SPINAL CORD DISORDER	Nervous system disorders	EG0001 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
SUBARACHNOID HAEMORRHAGE	Nervous system disorders	EG0001 affected2,642 at risk EG0011 affected2,634 at risk EG0020 affected842 at risk EG003
SYNCOPE	Nervous system disorders	EG00010 affected2,642 at risk EG0019 affected2,634 at risk EG0027 affected842 at risk EG003
TRANSIENT ISCHAEMIC ATTACK	Nervous system disorders	EG0004 affected2,642 at risk EG0018 affected2,634 at risk EG0021 affected842 at risk EG003
VASCULAR DEMENTIA	Nervous system disorders	EG0000 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
VERTEBRAL ARTERY OCCLUSION	Nervous system disorders	EG0001 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
PREGNANCY	Pregnancy, puerperium and perinatal conditions	EG0000 affected2,642 at risk EG0011 affected2,634 at risk EG0020 affected842 at risk EG003
ALCOHOL WITHDRAWAL SYNDROME	Psychiatric disorders	EG0001 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
ALCOHOLISM	Psychiatric disorders	EG0001 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
ANXIETY	Psychiatric disorders	EG0001 affected2,642 at risk EG0011 affected2,634 at risk EG0020 affected842 at risk EG003
COMPLETED SUICIDE	Psychiatric disorders	EG0000 affected2,642 at risk EG0011 affected2,634 at risk EG0021 affected842 at risk EG003
CONVERSION DISORDER	Psychiatric disorders	EG0001 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
DELIRIUM TREMENS	Psychiatric disorders	EG0000 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
DELUSION	Psychiatric disorders	EG0000 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
DEPRESSION	Psychiatric disorders	EG0002 affected2,642 at risk EG0012 affected2,634 at risk EG0020 affected842 at risk EG003
DEPRESSIVE SYMPTOM	Psychiatric disorders	EG0000 affected2,642 at risk EG0011 affected2,634 at risk EG0020 affected842 at risk EG003
MAJOR DEPRESSION	Psychiatric disorders	EG0000 affected2,642 at risk EG0011 affected2,634 at risk EG0020 affected842 at risk EG003
MENTAL STATUS CHANGES	Psychiatric disorders	EG0001 affected2,642 at risk EG0012 affected2,634 at risk EG0020 affected842 at risk EG003
PARANOIA	Psychiatric disorders	EG0001 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
PSYCHOTIC DISORDER	Psychiatric disorders	EG0001 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
SUICIDAL IDEATION	Psychiatric disorders	EG0001 affected2,642 at risk EG0011 affected2,634 at risk EG0020 affected842 at risk EG003
SUICIDE ATTEMPT	Psychiatric disorders	EG0000 affected2,642 at risk EG0011 affected2,634 at risk EG0020 affected842 at risk EG003
ACUTE PRERENAL FAILURE	Renal and urinary disorders	EG0001 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
BLADDER MASS	Renal and urinary disorders	EG0000 affected2,642 at risk EG0011 affected2,634 at risk EG0020 affected842 at risk EG003
BLADDER OBSTRUCTION	Renal and urinary disorders	EG0000 affected2,642 at risk EG0011 affected2,634 at risk EG0020 affected842 at risk EG003
CALCULUS URETERIC	Renal and urinary disorders	EG0001 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
CALCULUS URINARY	Renal and urinary disorders	EG0001 affected2,642 at risk EG0011 affected2,634 at risk EG0021 affected842 at risk EG003
DYSURIA	Renal and urinary disorders	EG0001 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
HAEMATURIA	Renal and urinary disorders	EG0004 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
HAEMORRHAGE URINARY TRACT	Renal and urinary disorders	EG0000 affected2,642 at risk EG0011 affected2,634 at risk EG0020 affected842 at risk EG003
HYDRONEPHROSIS	Renal and urinary disorders	EG0002 affected2,642 at risk EG0010 affected2,634 at risk EG0021 affected842 at risk EG003
HYDROURETER	Renal and urinary disorders	EG0001 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
HYPERTONIC BLADDER	Renal and urinary disorders	EG0000 affected2,642 at risk EG0011 affected2,634 at risk EG0020 affected842 at risk EG003
NEPHROLITHIASIS	Renal and urinary disorders	EG0003 affected2,642 at risk EG0014 affected2,634 at risk EG0020 affected842 at risk EG003
OBSTRUCTIVE UROPATHY	Renal and urinary disorders	EG0000 affected2,642 at risk EG0011 affected2,634 at risk EG0020 affected842 at risk EG003
RENAL ARTERY STENOSIS	Renal and urinary disorders	EG0004 affected2,642 at risk EG0011 affected2,634 at risk EG0020 affected842 at risk EG003
RENAL COLIC	Renal and urinary disorders	EG0001 affected2,642 at risk EG0011 affected2,634 at risk EG0020 affected842 at risk EG003
RENAL CYST	Renal and urinary disorders	EG0000 affected2,642 at risk EG0011 affected2,634 at risk EG0020 affected842 at risk EG003
RENAL FAILURE	Renal and urinary disorders	EG0002 affected2,642 at risk EG0012 affected2,634 at risk EG0020 affected842 at risk EG003
RENAL FAILURE ACUTE	Renal and urinary disorders	EG00012 affected2,642 at risk EG0017 affected2,634 at risk EG0022 affected842 at risk EG003
RENAL FAILURE CHRONIC	Renal and urinary disorders	EG0002 affected2,642 at risk EG0011 affected2,634 at risk EG0021 affected842 at risk EG003
URETERIC STENOSIS	Renal and urinary disorders	EG0000 affected2,642 at risk EG0011 affected2,634 at risk EG0020 affected842 at risk EG003
URETHRAL OBSTRUCTION	Renal and urinary disorders	EG0001 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
URINARY RETENTION	Renal and urinary disorders	EG0000 affected2,642 at risk EG0011 affected2,634 at risk EG0020 affected842 at risk EG003
BENIGN PROSTATIC HYPERPLASIA	Reproductive system and breast disorders	EG0001 affected2,642 at risk EG0013 affected2,634 at risk EG0021 affected842 at risk EG003
EPIDIDYMAL CYST	Reproductive system and breast disorders	EG0001 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
FEMALE GENITAL TRACT FISTULA	Reproductive system and breast disorders	EG0001 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
MENORRHAGIA	Reproductive system and breast disorders	EG0001 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
OVARIAN TORSION	Reproductive system and breast disorders	EG0000 affected2,642 at risk EG0010 affected2,634 at risk EG0021 affected842 at risk EG003
POSTMENOPAUSAL HAEMORRHAGE	Reproductive system and breast disorders	EG0000 affected2,642 at risk EG0011 affected2,634 at risk EG0020 affected842 at risk EG003
PROSTATOMEGALY	Reproductive system and breast disorders	EG0001 affected2,642 at risk EG0011 affected2,634 at risk EG0020 affected842 at risk EG003
ACUTE PULMONARY OEDEMA	Respiratory, thoracic and mediastinal disorders	EG0003 affected2,642 at risk EG0011 affected2,634 at risk EG0020 affected842 at risk EG003
ACUTE RESPIRATORY FAILURE	Respiratory, thoracic and mediastinal disorders	EG0001 affected2,642 at risk EG0014 affected2,634 at risk EG0021 affected842 at risk EG003
ASTHMA	Respiratory, thoracic and mediastinal disorders	EG0001 affected2,642 at risk EG0011 affected2,634 at risk EG0020 affected842 at risk EG003
ATELECTASIS	Respiratory, thoracic and mediastinal disorders	EG0000 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
BRONCHOSPASM	Respiratory, thoracic and mediastinal disorders	EG0000 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
CHRONIC OBSTRUCTIVE PULMONARY DISEASE	Respiratory, thoracic and mediastinal disorders	EG00014 affected2,642 at risk EG00111 affected2,634 at risk EG0026 affected842 at risk EG003
COUGH	Respiratory, thoracic and mediastinal disorders	EG0001 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
DYSPNOEA	Respiratory, thoracic and mediastinal disorders	EG00010 affected2,642 at risk EG0014 affected2,634 at risk EG0022 affected842 at risk EG003
DYSPNOEA EXERTIONAL	Respiratory, thoracic and mediastinal disorders	EG0000 affected2,642 at risk EG0012 affected2,634 at risk EG0020 affected842 at risk EG003
EPISTAXIS	Respiratory, thoracic and mediastinal disorders	EG0003 affected2,642 at risk EG0012 affected2,634 at risk EG0020 affected842 at risk EG003
HAEMOPTYSIS	Respiratory, thoracic and mediastinal disorders	EG0001 affected2,642 at risk EG0011 affected2,634 at risk EG0020 affected842 at risk EG003
HYPERCAPNIA	Respiratory, thoracic and mediastinal disorders	EG0000 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
INTERSTITIAL LUNG DISEASE	Respiratory, thoracic and mediastinal disorders	EG0001 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
LARYNGEAL STENOSIS	Respiratory, thoracic and mediastinal disorders	EG0000 affected2,642 at risk EG0011 affected2,634 at risk EG0020 affected842 at risk EG003
LARYNGOSPASM	Respiratory, thoracic and mediastinal disorders	EG0002 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
NASAL SEPTUM DEVIATION	Respiratory, thoracic and mediastinal disorders	EG0001 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
NASAL TURBINATE HYPERTROPHY	Respiratory, thoracic and mediastinal disorders	EG0001 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
PLEURAL EFFUSION	Respiratory, thoracic and mediastinal disorders	EG0002 affected2,642 at risk EG0011 affected2,634 at risk EG0020 affected842 at risk EG003
PLEURITIC PAIN	Respiratory, thoracic and mediastinal disorders	EG0000 affected2,642 at risk EG0010 affected2,634 at risk EG0021 affected842 at risk EG003
PNEUMONIA ASPIRATION	Respiratory, thoracic and mediastinal disorders	EG0000 affected2,642 at risk EG0011 affected2,634 at risk EG0020 affected842 at risk EG003
PNEUMOTHORAX	Respiratory, thoracic and mediastinal disorders	EG0000 affected2,642 at risk EG0012 affected2,634 at risk EG0020 affected842 at risk EG003
PULMONARY ARTERIAL HYPERTENSION	Respiratory, thoracic and mediastinal disorders	EG0000 affected2,642 at risk EG0011 affected2,634 at risk EG0020 affected842 at risk EG003
PULMONARY EMBOLISM	Respiratory, thoracic and mediastinal disorders	EG0006 affected2,642 at risk EG0016 affected2,634 at risk EG0020 affected842 at risk EG003
PULMONARY FIBROSIS	Respiratory, thoracic and mediastinal disorders	EG0001 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
PULMONARY MASS	Respiratory, thoracic and mediastinal disorders	EG0000 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
PULMONARY OEDEMA	Respiratory, thoracic and mediastinal disorders	EG0000 affected2,642 at risk EG0012 affected2,634 at risk EG0020 affected842 at risk EG003
RESPIRATORY DISTRESS	Respiratory, thoracic and mediastinal disorders	EG0001 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
RESPIRATORY FAILURE	Respiratory, thoracic and mediastinal disorders	EG0003 affected2,642 at risk EG0013 affected2,634 at risk EG0020 affected842 at risk EG003
SLEEP APNOEA SYNDROME	Respiratory, thoracic and mediastinal disorders	EG0001 affected2,642 at risk EG0011 affected2,634 at risk EG0020 affected842 at risk EG003
ANGIOEDEMA	Skin and subcutaneous tissue disorders	EG0001 affected2,642 at risk EG0011 affected2,634 at risk EG0020 affected842 at risk EG003
DIABETIC ULCER	Skin and subcutaneous tissue disorders	EG0000 affected2,642 at risk EG0011 affected2,634 at risk EG0020 affected842 at risk EG003
PEMPHIGOID	Skin and subcutaneous tissue disorders	EG0000 affected2,642 at risk EG0011 affected2,634 at risk EG0020 affected842 at risk EG003
RASH	Skin and subcutaneous tissue disorders	EG0000 affected2,642 at risk EG0011 affected2,634 at risk EG0021 affected842 at risk EG003
RASH PAPULAR	Skin and subcutaneous tissue disorders	EG0001 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
SKIN ULCER	Skin and subcutaneous tissue disorders	EG0001 affected2,642 at risk EG0012 affected2,634 at risk EG0020 affected842 at risk EG003
CORONARY ARTERY BYPASS	Surgical and medical procedures	EG0000 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
IMPLANTABLE DEFIBRILLATOR REPLACEMENT	Surgical and medical procedures	EG0001 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
INGUINAL HERNIA REPAIR	Surgical and medical procedures	EG0001 affected2,642 at risk EG0011 affected2,634 at risk EG0020 affected842 at risk EG003
MITRAL VALVE REPLACEMENT	Surgical and medical procedures	EG0000 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
ANEURYSM	Vascular disorders	EG0001 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
AORTIC ANEURYSM	Vascular disorders	EG0005 affected2,642 at risk EG0011 affected2,634 at risk EG0021 affected842 at risk EG003
AORTIC STENOSIS	Vascular disorders	EG0004 affected2,642 at risk EG0012 affected2,634 at risk EG0020 affected842 at risk EG003
AORTITIS	Vascular disorders	EG0001 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
ARTERIAL OCCLUSIVE DISEASE	Vascular disorders	EG0000 affected2,642 at risk EG0011 affected2,634 at risk EG0020 affected842 at risk EG003
ARTERIAL STENOSIS	Vascular disorders	EG0000 affected2,642 at risk EG0010 affected2,634 at risk EG0021 affected842 at risk EG003
ARTERIOSCLEROSIS	Vascular disorders	EG0000 affected2,642 at risk EG0013 affected2,634 at risk EG0020 affected842 at risk EG003
DEEP VEIN THROMBOSIS	Vascular disorders	EG0004 affected2,642 at risk EG0012 affected2,634 at risk EG0021 affected842 at risk EG003
FEMORAL ARTERIAL STENOSIS	Vascular disorders	EG0002 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
FEMORAL ARTERY OCCLUSION	Vascular disorders	EG0000 affected2,642 at risk EG0011 affected2,634 at risk EG0020 affected842 at risk EG003
HAEMATOMA	Vascular disorders	EG0002 affected2,642 at risk EG0011 affected2,634 at risk EG0022 affected842 at risk EG003
HYPERTENSION	Vascular disorders	EG0004 affected2,642 at risk EG0014 affected2,634 at risk EG0020 affected842 at risk EG003
HYPERTENSIVE CRISIS	Vascular disorders	EG0001 affected2,642 at risk EG0013 affected2,634 at risk EG0021 affected842 at risk EG003
HYPERTENSIVE EMERGENCY	Vascular disorders	EG0001 affected2,642 at risk EG0011 affected2,634 at risk EG0020 affected842 at risk EG003
HYPOTENSION	Vascular disorders	EG0002 affected2,642 at risk EG0011 affected2,634 at risk EG0020 affected842 at risk EG003
ILIAC ARTERY OCCLUSION	Vascular disorders	EG0001 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
INTERMITTENT CLAUDICATION	Vascular disorders	EG0007 affected2,642 at risk EG0011 affected2,634 at risk EG0020 affected842 at risk EG003
ISCHAEMIA	Vascular disorders	EG0000 affected2,642 at risk EG0011 affected2,634 at risk EG0020 affected842 at risk EG003
MALIGNANT HYPERTENSION	Vascular disorders	EG0002 affected2,642 at risk EG0011 affected2,634 at risk EG0020 affected842 at risk EG003
ORTHOSTATIC HYPOTENSION	Vascular disorders	EG0000 affected2,642 at risk EG0011 affected2,634 at risk EG0020 affected842 at risk EG003
PELVIC VENOUS THROMBOSIS	Vascular disorders	EG0000 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
PERIPHERAL ARTERIAL OCCLUSIVE DISEASE	Vascular disorders	EG0001 affected2,642 at risk EG0015 affected2,634 at risk EG0022 affected842 at risk EG003
PERIPHERAL ISCHAEMIA	Vascular disorders	EG0000 affected2,642 at risk EG0013 affected2,634 at risk EG0021 affected842 at risk EG003
PERIPHERAL VASCULAR DISORDER	Vascular disorders	EG0000 affected2,642 at risk EG0014 affected2,634 at risk EG0021 affected842 at risk EG003
SUBCLAVIAN ARTERY STENOSIS	Vascular disorders	EG0001 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
THROMBOPHLEBITIS SUPERFICIAL	Vascular disorders	EG0001 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
THROMBOSIS	Vascular disorders	EG0001 affected2,642 at risk EG0010 affected2,634 at risk EG0020 affected842 at risk EG003
VARICOSE VEIN	Vascular disorders	EG0000 affected2,642 at risk EG0011 affected2,634 at risk EG0020 affected842 at risk EG003
VASCULAR CALCIFICATION	Vascular disorders	EG0000 affected2,642 at risk EG0011 affected2,634 at risk EG0020 affected842 at risk EG003

ID	Title	Description	Serious Events (Affected)	Serious Events (At Risk)
EG000	HCRI DAPT - DES 30-month DAPT	Patients who were enrolled by HCRI into the HCRI DAPT Study, treated with DES at the index procedure and randomized at 12 months post procedure to receive a total of 30 months of DAPT	617	2,642
EG001	HCRI DAPT - DES 12-month DAPT	Patients who were enrolled by HCRI into the HCRI DAPT Study, treated with DES at the index procedure and randomized at 12 months post procedure to receive a total of 12 months of DAPT	572	2,634
EG002	HCRI DAPT - BMS 30-month DAPT	Patients who were enrolled by HCRI into the HCRI DAPT Study, treated with BMS at the index procedure and randomized at 12 months post procedure to receive a total of 30 months of DAPT	144	842
EG003	HCRI DAPT - BMS 12-month DAPT	Patients who were enrolled by HCRI into the HCRI DAPT Study, treated with BMS at the index procedure and randomized at 12 months post procedure to receive a total of 12 months of DAPT	150	845

ID	Term
D003324	Coronary Artery Disease
D054058	Acute Coronary Syndrome
D009203	Myocardial Infarction
D017202	Myocardial Ischemia

ID	Term
D003327	Coronary Disease
D006331	Heart Diseases
D002318	Cardiovascular Diseases
D001161	Arteriosclerosis
D001157	Arterial Occlusive Diseases
D014652	Vascular Diseases
D007238	Infarction
D007511	Ischemia
D010335	Pathologic Processes
D013568	Pathological Conditions, Signs and Symptoms
D009336	Necrosis

ID	Term
D012459	Salicylates
D062385	Hydroxybenzoates
D010636	Phenols
D001555	Benzene Derivatives
D006841	Hydrocarbons, Aromatic
D006844	Hydrocarbons, Cyclic
D006838	Hydrocarbons
D009930	Organic Chemicals
D013988	Ticlopidine
D058924	Thienopyridines
D013876	Thiophenes
D013457	Sulfur Compounds
D011725	Pyridines
D006573	Heterocyclic Compounds, 1-Ring
D006571	Heterocyclic Compounds
D006574	Heterocyclic Compounds, 2-Ring
D000072471	Heterocyclic Compounds, Fused-Ring
D010879	Piperazines

ID	Title	Description
BG000	DES 30-month DAPT	Patients who were treated with DES at the index procedure and were randomized at 12 months post procedure to receive a total of 30 months of DAPT
BG001	DES 12-month DAPT	Patients who were treated with DES at the index procedure and were randomized at 12 months post procedure to receive a total of 12 months of DAPT
BG002	BMS 30-month DAPT	Patients who were treated with BMS at the index procedure and were randomized at 12 months post procedure to receive a total of 30 months of DAPT
BG003	BMS 12-month DAPT	Patients who were treated with BMS at the index procedure and were randomized at 12 months post procedure to receive a total of 12 months of DAPT
BG004	Total	Total of all reporting groups

ID	Term
D001241	Aspirin
D000077144	Clopidogrel
D000068799	Prasugrel Hydrochloride